tirzepatide vs semaglutide weight loss efficacy side effects Dynamics and Health Burden Changes with versus Tirzepatide on ingestive behavior in

Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment

In addition, 31.6% of Zepbound participants lost 25% of body weight compared to 16.1% of participants who used Wegovy

Minelli C, Granell R, Newson R, Rose-Zerilli MJ, Torrent M, Ring SM, et al

Eligible beneficiaries must meet the clinical criteria at the time of GLP-1 therapy initiation

Considering these findings observed across a large, real-world cohort, the researchers concluded that avoidance of semaglutide based solely on concerns regarding the risk of NAION may not be warranted, as its potential benefits for blood glucose control and cardiovascular health likely outweigh its potential risks.